Abstract: A method for automatically assessing information processing speed in a test subject is disclosed. In the inventive method, a first qualimetric activity parameter for sensorial transmission, cognition and motoric output activity is determined and a second qualimetric activity parameter for sensorial transmission and motoric output activity is determined. A third qualimetric activity parameter for cognition is determined by comparing the first and the second qualimetric activity parameters to each other, and the information processing speed in the test subject is assessed based on the first, second and third qualimetric activity parameters. The information processing speed can be determined by comparing the determined qualimetric activity parameters to a reference and the subject's cognitive impairment can then be determined from the processing speed. The inventive method can be computer implemented. A mobile device or system for carrying out the disclosed methods is also disclosed.

Abstract: The method includes fixing the tissue sample with a first fixation solution immersing the tissue sample in a delipidation solution including a chaotropic agent configured to induce a swelling of the sample; staining the tissue sample; dehydrating the tissue sample in an organic dehydration solution, the dehydration solution configured to induce a shrinking of the sample; and immersing the fixed tissue sample in an organic clearing solution.

Abstract: The present invention relates to multispecific antibodies comprising at least three antigen binding sites wherein the third binding site is disulfide stabilized by introduction of cysteine, method for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Abstract: The present invention generally relates to the provision of means and methods for preparing protein compositions. The invention provides a method comprising the steps of (i) contacting a starting composition comprising a protein with a hydrolase inhibitor, wherein the hydrolase inhibitor is immobilized on a solid carrier; (ii) recovering a composition comprising the protein. Furthermore, the invention relates to a method for preparing a protein formulation comprising the steps of (i) contacting a starting composition comprising a protein with a hydrolase inhibitor, wherein the hydrolase inhibitor is immobilized on a solid carrier; (ii) recovering a composition comprising the protein, wherein the method for preparing the protein formulation further comprises adding a surfactant, preferably a fatty acid ester, to the composition comprising the protein.

Abstract: The present invention relates to anti-VEGF antibodies and methods of their production and their use.

Abstract: Embodiments disclosed herein generally relate to multi-arm machine learning models for lesion detection. Particularly, aspects of the present disclosure are directed to accessing a three-dimensional magnetic resonance imaging (MRI) images. Each of the three-dimensional MRI images depict a same volume of a brain of a subject. The volume of the brain includes at least part of one or more lesions. Each three-dimensional MRI image of the three-dimensional MRI images is processed using one or more corresponding encoder arms of a machine-learning model to generate an encoding of the three-dimensional MRI image. The encodings of the three-dimensional MRI images are concatenated to generate a concatenated representation. The concatenated representation is processed using a decoder arm of the machine-learning model to generate a prediction that identifies one or more portions of the volume of the brain predicted to depict at least part of a lesion.

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

Abstract: The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.

Abstract: The method includes generating, for each of a plurality of original images, a first artificially degraded image by applying a first image-artifact-generation logic on each of the original images; and generating the program logic by training an untrained version of a first machine-learning logic that encodes a first artifacts-removal logic on the original images and their respectively generated first degraded images; and returning the trained first machine-learning logic as the program logic or as a component thereof. The first image-artifact-generation logic is A) an image-acquisition-system-specific image-artifact-generation logic or B) a tissue-staining-artifact-generation logic.

Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.

Abstract: The invention relates to a method of identifying a biomarker in a tissue sample. The method comprises receiving an acquired image depicting a tissue sample, the pixel intensity values of the acquired image correlating with an autofluorescence signal or of an X-ray induced signal or a signal of a non-biomarker specific stain or a signal of a first biomarker specific stain adapted to selectively stain a first biomarker. The acquired image is input into a trained machine learning logic—MLL which automatically transforms the acquired image into an output image highlighting tissue regions predicted to comprise a second biomarker.

Abstract: Methods and systems disclosed herein relate generally to systems and methods for predicting a future visual acuity of a subject by using machine-learning models. An image of at least part of a retina of a subject can be processed by one or more first machine-learning models to detect a set of retina-related segments. Segment-specific metrics that characterize a retina-related segment of the set of retina-related segments can be generated. The segment-specific metrics can be processed by using a second machine-learning model to generate a result corresponding to a prediction corresponding to a future visual acuity of the subject.

Abstract: A force testing machine (FTM) validation apparatus is disclosed for validating a test process involving a force testing machine to measure forces involved in operation of a syringe arrangement. Particularly a syringe arrangement that includes a staked-in needle prefilled syringe and a needle safety device cooperating with the staked-in needle prefilled syringe. The FTM validation apparatus includes a syringe arrangement surrogate, and a holder arranged to support the syringe arrangement surrogate in a predefined position and orientation in the force testing machine. The syringe arrangement surrogate includes a break loose part arranged to mimic a break loose force of the syringe arrangement and an injection force part arranged to mimic an injection force of the syringe arrangement. Methods are also disclosed for validating a test process that measures forces involved in operation of a syringe arrangement and for measuring forces involved in operation of the syringe arrangement.

Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

Abstract: Herein is reported a method for the production of an immunoglobulin comprising the following steps: a) providing a eukaryotic cell comprising a nucleic acid encoding the immunoglobulin, b) cultivating the eukaryotic cell in a cultivation medium wherein the amount of glucose available in the cultivation medium per time unit is kept constant and limited to less than 80% of the amount that could maximally be utilized by the cells in the cultivation medium per time unit, and c) recovering the immunoglobulin from the culture.

Abstract: The invention relates to a comparison unit (130) configured for determining if a first pH measuring device of a first tank (104; 106) is affected by a pH-measuring problem, the comparison unit being configured for: —receiving a first CO2 concentration and a first pH value, the first CO2 concentration being a CO2 concentration of a first gas volume above a medium in a first tank, the first CO2 concentration and the first pH value being measured at a first time when the medium in the first tank is in pH-CO2 equilibrium state with the first gas volume and before said equilibrium state is modified by the metabolism of a cell culture in the first tank, the first pH value being a measured value provided by a first pH measuring device operatively coupled to the first tank (102); —receiving a second CO2 concentration and a second pH value, the second CO2 concentration being a CO2 concentration of a second gas volume above a medium in a second tank, the second CO2 concentration and the second pH value being measured a

Abstract: Methods and systems for online sampling an aliquot from a mobile phase comprising an analyte for producing a pharmaceutical or chemical product, wherein the apparatus comprises an analytical device and a tube between an inlet and an outlet, wherein the outlet is in fluid communication with the analytical device, the method comprising: providing a sample device comprising a needle with a needle tip, a septum pierceable by the needle and a pump, wherein the needle is moveable between an extended position in which the septum is pierced by the needle, and a retracted position, in which the septum is not pierced, disposing the sample device at the curved portion of the tube, moving the needle to the extended position such that the needle tip faces the flow direction, and drawing out an aliquot out of the mobile phase.

Abstract: The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.

Abstract: A method of preparing a double chamber container is disclosed that includes filling a substance into the container, freeze-drying the substance therein, inserting a middle plunger in the container to form distal and proximal chambers, wherein the middle plunger seals the distal chamber from the proximal chamber and the freeze-dried substance is inside the distal chamber. The method includes filling a reconstitution medium in the proximal chamber, and sealing distal and proximal openings of the container. The method includes providing a holder having a seat and arranging the container in the seat in an upright position wherein a distal end side of the container extends downwardly and a proximal end side of the container extends upwardly. The container is arranged in the seat while the substance is filled, the substance is freeze-dried, the middle plunger is inserted, the reconstitution medium is filled, and the proximal opening is sealed.